# Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

> **NCT00654238** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 59 (actual)

## Conditions studied

- Metastatic Differentiated Thyroid Cancer
- Metastatic Poorly Differentiated Thyroid Cancer
- Metastatic Anaplastic Thyroid Cancer
- Metastatic Medullary Thyroid Cancer

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT00654238
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654238, "Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00654238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*